Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned using combinations of vorinostat with other drugs.
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Yale University
- Target Recruit Count
- 17
- Registration Number
- NCT00785798
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 52
- Registration Number
- NCT00776503
- Locations
- 🇫🇷
CH René Dubos, Cergy-pontoise, France
🇫🇷Hematology Dpt, Hôpital Sud Francilien, Corbeil-essonnes, France
🇫🇷Hôpital de la Durance, Avignon, France
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT00773838
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 637
- Registration Number
- NCT00773747
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00771472
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00764517
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2013-07-25
- Target Recruit Count
- 19
- Registration Number
- NCT00762255
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00744354
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00735826
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 125
- Registration Number
- NCT00731731
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
🇺🇸Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.